Background-Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting Ͼ2 million patients in the United States alone. Despite decades of research, surprisingly little is known regarding the molecular pathways underlying the pathogenesis of AF. ANK2 encodes ankyrin-B, a multifunctional adapter molecule implicated in membrane targeting of ion channels, transporters, and signaling molecules in excitable cells. Methods and Results-In the present study, we report early-onset AF in patients harboring loss-of-function mutations in ANK2. In mice, we show that ankyrin-B deficiency results in atrial electrophysiological dysfunction and increased susceptibility to AF. Moreover, ankyrin-B ϩ/Ϫ atrial myocytes display shortened action potentials, consistent with human AF. Ankyrin-B is expressed in atrial myocytes, and we demonstrate its requirement for the membrane targeting and function of a subgroup of voltage-gated Ca 2ϩ channels (Ca v 1.3) responsible for low voltage-activated L-type Ca
A trial fibrillation (AF), which is characterized by rapid and irregular activation of the atrium, is the most common sustained arrhythmia found in clinical practice, affecting Ϸ2.3 million people in the United States alone. 1 The prevalence of AF increases with age, with Ϸ2% to 6% of people aged Ͼ65 years exhibiting AF. 2, 3 Given the demographics of the United States, it is predicted that there will be a 5-fold increase in the prevalence of AF by 2050. 4 Although AF is frequently associated with other cardiac disorders including coronary artery disease, mitral valve disease, congenital heart disease, and congestive heart failure, Ϸ30% of all AF cases are described as lone AF, in which patients exhibit no previous cardiac pathology. 5 The majority of monogenic AF cases described to date are linked to mutations that affect potassium channels, although these cases represent only a small fraction of total monogenic AF cases. 6 
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Ankyrin-B (encoded by ANK2) is an adapter protein expressed in a number of excitable cells including neurons, cardiomyocytes, and pancreatic ␤ cells. 7 Given that ankyrin-B targets select ion channels, transporters, and signaling molecules to specific membrane domains, it is not surprising that dysfunction in the ankyrin-B cellular pathway has been linked to neuronal defects, ventricular arrhythmia, and neonatal diabetes. 8 -10 In the present study, we demonstrate a critical role for ankyrin-B in atrial function. Individuals harboring loss-offunction mutations in ANK2 developed early-onset AF. Ankyrin-B-deficient mice phenocopied ANK2-based human disease and displayed striking susceptibility to AF. Primary atrial myocytes from ankyrin-B-deficient mice displayed shortened action potentials, a hallmark of AF, and this decrease was associated with loss of L-type Ca 2ϩ current (I Ca,L ). Our data revealed that Ca v 1.3 is a novel ankyrin-Bbinding partner, and the structural requirements for ankyrin-B/Ca v 1.3 association were mapped. Specifically, a unique C-terminal motif in Ca v 1.3 was found to be necessary and sufficient for ankyrin binding. In ankyrin-B ϩ/Ϫ atrial myocytes, Ca v 1.3 protein expression and membrane function were reduced. Moreover, we demonstrated that ankyrin-B levels are reduced in human AF, providing an association between ankyrin-B and the pathogenesis of AF. Together, our data describe a novel mechanism for Ca v 1.3 membrane targeting in primary atrial cardiomyocytes and reveal a potential molecular mechanism underlying ankyrin-associated AF.
Methods

Immunofluorescence
Myocytes were washed with phosphate-buffered saline (pH 7.4) and fixed in warm 2% paraformaldehyde (37°C). Cells were blocked/ permeabilized in phosphate-buffered saline containing 0.075% Triton X-100 and 3% fish oil gelatin (Sigma) and incubated in primary antibody overnight at 4°C. After washes (phosphate-buffered saline plus 0.1% Triton X-100), cells were incubated in secondary antibody (Alexa 488 and 568 and ToPro-3AM 633) for 8 hours at 4°C and mounted with the use of Vectashield (Vector). Images were collected on a Zeiss 510 Meta confocal microscope (40-power oil, 1.40 numerical aperture, pinhole equals 1.0 Airy Disc) with Zeiss Imaging software. Images were imported into Adobe Photoshop for cropping and linear contrast adjustment. Imaging experiments were performed at least 3 times for each experimental protocol, and Ͼ20 myocytes were examined from each experimental set.
Immunoblots
Protein lysates were isolated from atria and ventricles of wild-type (WT) and heterozygous ankyrin-B mice as described. 11 Antibodies and tissues are described in the online-only Data Supplement.
Cellular Electrophysiology
Membrane currents and action potentials were measured with an Axon 200B patch-clamp amplifier controlled by a personal computer with the use of a Digidata 1320A acquisition board driven by pClamp 8.0 software (Axon Instruments). Electrophysiological recordings were obtained only from Ca 2ϩ -tolerant, rod-shaped atrial cells. We used a perforated (amphotericin B) patch for calcium current and action potential studies. All experiments were conducted at room temperature, unless otherwise noted. Other currents were measured as described. 12 Recording pipettes, fabricated from borosilicate glass, had resistance of 2 to 4 mol/L⍀ when filled with recording solution. All solutions were adjusted to 275 to 295 mOsm.
Statistical Analysis
For human data, differences between group means were compared by unpaired Student t test. Frequency data were analyzed with the Fisher exact test. The Kolmogorov-Smirnov test was used to test whether data followed a normal distribution. 
Human Tissue Samples
Human tissue experimental protocols were approved by the ethics committee of the Medical Faculty Mannheim, University of Heidelberg (No. 2011-216N-MA). Each patient gave written informed consent. During routine cannulation procedures in patients undergoing open-heart surgery for cardiac bypass grafting and valve replacement, the tip of the right atrial appendage was removed and immediately snap-frozen in liquid nitrogen. Appendages were obtained from 12 sinus rhythm and 10 paroxysmal AF (Table II in the on-line only Data Supplement) patients. The AF group included patients in sinus rhythm at surgery with a history of at least 1 episode of self-terminating AF lasting Ͻ7 days (paroxysmal AF patients).
Additional methods are presented in the online-only Data Supplement.
Results
Ankyrin-B Dysfunction Is Associated With Human AF
We identified a high incidence of AF in ANK2 mutationpositive probands. Probands harboring ANK2 loss-of-function alleles displayed early-onset AF, commonly progressing to permanent AF. 9, 13, 14 In 1 large kindred (74 members), 13 of 25 ANK2 loss-of-function variant carriers (phenotypes previously mapped to ANK2; Z max ϭ7.05 9 ) displayed AF (mean onset, 40Ϯ18 years; 5 paroxysmal, 8 permanent), whereas noncarriers were asymptomatic. Only 2 individuals were nonpenetrant for atrial phenotypes. The others had AF, AF with sinus node dysfunction, or sinus node dysfunction alone. In an unrelated large family, 20 of 36 individuals were positive for the ANK2 disease allele (maximal logarithm of odds score was for marker D4S1616; linkage Z max ϭ5.9, ϭ0), and 3 of 20 disease allele carriers displayed AF (mean onset, 48Ϯ12 years; 2 paroxysmal, 1 permanent), whereas 13 displayed sinus node disease requiring pacemaker implantation (mean age for implantation, 30Ϯ18 years 12 ). Only 4 individuals were nonpenetrant for atrial phenotypes. In addition to AF, prior work demonstrates that ANK2 variant carriers may display prolonged ventricular QT intervals, which predisposes individuals to ventricular arrhythmias (examples of cardiac phenotypes are presented in Table I in the online-only Data Supplement). 9, 13 Because AF and long-QT syndrome are often associated with opposing action potential characteristics (ie, AF with shortened atrial action potentials and long-QT syndrome with prolonged ventricular action potentials), we hypothesized that ankyrin-B might uniquely affect atrial ion channels, resulting in an increased susceptibility to AF.
Mice Deficient for Ankyrin-B Expression Display Atrial Dysfunction
Previous studies have demonstrated that human ANK2 gene mutations linked with arrhythmia behave as loss of function when analyzed in primary cardiomyocytes. 9, [12] [13] [14] Therefore, we assessed the role of ankyrin-B deficiency in atria of mice heterozygous for a null mutation in ankyrin-B (ankyrin-B ϩ/Ϫ mice, because ankyrin-B Ϫ/Ϫ mice die at birth). Continuous telemetry ECG recordings from conscious ankyrin-B ϩ/Ϫ mice revealed atrial arrhythmias also present in human carriers of ANK2 variants, including spontaneous bradycardia with erratic atrial activity, lack of discrete P waves, and variable ventricular response ( Figure  1A through 1D) . We next tested the susceptibility to atrial arrhythmias in ankyrin-B ϩ/Ϫ mice after atrial burst pacing. 15 Intracardiac electrograms were recorded simultaneously with the surface ECG to confirm the nature of abnormal atrial electric activities. Periods of pacing-induced AF were observed in the majority (Ϸ75%) of ankyrin-B ϩ/Ϫ mice (11 of 15 mice; Figure 1E and 1F). In contrast, a significantly lower fraction of WT mice demonstrated AF inducibility with the use of this protocol (2 of 9 WT mice; PϽ0.05 versus ankyrin-B ϩ/Ϫ ; Figure 1F ). Ankyrin-B ϩ/Ϫ atrial episodes showed characteristic absence of P waves and RR-interval variability. 15 Moreover, AF/atrial tachycardia was confirmed by the presence of rapid and irregular A waves on the atrioventricular electrogram ( Figure 1E) . Together, the electrophysiological data in human ANK2 mutation carriers and ankyrin-B ϩ/Ϫ mice clearly demonstrate that ankyrin-B dysfunction is detrimental for normal atrial electric activity.
Ankyrin-B Is Expressed in Atria
We used immunoblot to identify ankyrin-B expression patterns in human atria. Ankyrin-B was expressed in all human heart chambers at similar levels ( Figure 2A ). As expected, voltagegated calcium channel Ca v 1.2 was most abundant in the right and left ventricles, whereas Ca v 1.3 was enriched in the right and left atria compared with ventricle 16 (Figure 2A ). At the level of the single atrial cardiomyocyte, ankyrin-B was present at both the peripheral sarcolemma ( Figure 2B , yellow arrows) and the M line ( Figure 2B , white arrows). These data demonstrate that ankyrin-B is expressed in atrial tissue and localized at select membrane domains in isolated primary atrial cells. 
Ankyrin-B ؉/؊ Atrial Myocytes Display Aberrant Atrial Electric Activity
To define the role of ankyrin-B in atria, we evaluated action potentials from isolated WT and ankyrin-B ϩ/Ϫ atrial cardiomyocytes. Notably, ankyrin-B ϩ/Ϫ atrial myocytes displayed significantly reduced action potential duration (APD) (measured at 90% of repolarization [APD 90 ]) compared with WT atrial cardiomyocytes ( Figure 2C and 2D) . In fact, APD 90 was reduced Ϸ25% in ankyrin-B ϩ/Ϫ atrial cardiomyocytes at both room (Figure 2C and 2D ; nϭ7 WT, nϭ8 ankyrin-B ϩ/Ϫ ; PϽ0.05) and physiological temperatures ( Figure I in the online-only Data Supplement; nϭ6 WT, nϭ5 ankyrin-B ϩ/Ϫ ; PϽ0.05), a cellular phenotype consistent with that observed in AF patients. 17 In contrast, prior studies revealed that ankyrin-B ϩ/Ϫ ventricular cardiomyocytes do not display significant differences in APD 90 compared with WT. 9 Atrial myocyte depolarization and repolarization are regulated by the synchronized activities of membrane-associated ion channels, transporters, and pumps. To define the molecular basis of action potential shortening in ankyrin-B ϩ/Ϫ atrial myocytes, we investigated the activities of a number of critical atrial myocyte currents. We observed a significantly reduced I Ca,L in ankyrin-B ϩ/Ϫ atrial myocytes (Figure 2E and 2F; nϭ7 WT, nϭ8 ankyrin-B ϩ/Ϫ ; PϽ0.05) in contrast to ankyrin-B ϩ/Ϫ ventricular myocytes that display normal I Ca,L and APD. 9 We observed no difference in I Na (Figure 2G 
Ankyrin-B Is Directly Associated With Ca v 1.3
On the basis of electrophysiological data from primary myocytes and fibroblasts showing reduced Ca v 1.3 in ankyrin-B-deficient atrial myocytes, we tested for a direct interaction between ankyrin-B and Ca v 1.3. Full-length Ca v 1.3 has 5 major cytoplasmic domains including an amino terminal domain, 3 cytoplasmic segments that connect the 4 major transmembrane regions (DI through DIV), and a large C-terminal domain ( Figure 4A ). We generated radiolabeled purified protein of each Ca v 1.3 cytoplasmic region (N1, L1 through L3, C1 through C4). Because of the extensive length of the C-terminal domain, this region was further subdivided into 4 segments for direct binding experiments ( Figure 4A , C1 through C4). We observed significant association between glutathione-S-transferase-labeled ankyrin-B membranebinding domain and only 1 intracellular region of Ca v 1.3, the C4 region of the C-terminus (residues 2014 to 2203; Figure  4B ). This interaction was specific to ankyrin-B because it was not observed for the similar ankyrin-G membrane-binding domain or glutathione-S-transferase alone ( Figure 4B ). These data support a direct and specific interaction between ankyrin-B membrane-binding domain and the C-terminal domain of Ca v 1.3. Although our functional data suggested a specific interaction of ankyrin-B with Ca v 1.3, Ca v 1.2 and Ca v 1.3 share significant sequence similarity in the distal C-terminal regions (residues 2014 to 2203 of Ca v 1.3; Figure 4C ). We therefore tested for the interaction of the ankyrin-B membrane-binding domain with both Ca v 1.2 and Ca v 1.3 C-terminal domains (residues 1958 to 2159 of Ca v 1.2). Consistent with our previous imaging, biochemical, and functional data, we observed no interaction of ankyrin-B or ankyrin-G with the Ca v 1.2 C-terminal domain ( Figure 4D ). The Ca v 1.3 but not Ca v 1.2 C-terminal domain contains a short motif resembling the ankyrin-binding sequence found in voltage-gated Na v channels (ie, Na v 1.2, Na v 1.5) and inwardly rectifying K ϩ channels (ie, Kir6.2; Figure 4E ). 8, 20, 21 Importantly, this sequence is conserved across Ca v 1.3 orthologs ( Figure 4F) . We tested the requirement of this motif for ankyrin-B binding using a mutant C-terminal domain lacking these residues ( Figure 4G ). Although Ca v 1.3 C-terminal domain was associated with ankyrin-B (but not ankyrin-G), Ca v 1.3 C4 ⌬ankyrin-binding domain lacking the putative ankyrin-binding domain failed to associate with ankyrin-B ( Figure 4H ). On the basis of these results, we tested whether residues 2175 to 2198 were sufficient for ankyrin-binding using biotinylated peptides. We observed an association of full-length endogenous ankyrin-B from human atrial lysates with an immobilized peptide containing the ankyrin-Bbinding domain in Ca v 1.3 ( Figure 4I and 4J) . We observed no interaction with a peptide of the corresponding region in Ca v 1.2 or with streptavidin beads alone ( Figure 4J ). Together, our data demonstrate that Ca v 1.3 residues 2175 to 2198 are necessary and sufficient for direct ankyrin-B association.
To test whether Ca v 1.3 membrane expression requires a direct interaction with ankyrin-B, we measured I Ca,L in primary cardiac fibroblasts expressing WT Ca v 1.3 and a mutant Ca v 1.3 lacking the ankyrin-binding motif. As expected, WT Ca v 1.3 expression resulted in robust I Ca,L in primary cells (Figure 4K; nϭ7; PϽ0.05) . In contrast, Ca v 1.3⌬2174 lacking the ankyrin-B-binding motif displayed Ͼ50% reduction in membrane activity compared with the WT channel (Figure 4K ; nϭ7; PϽ0.05). These data support the requirement of a direct ankyrin-B interaction for Ca v 1.3 membrane targeting. However, these data also suggest that an ankyrin-independent pathway(s) also plays a critical role in Ca v 1.3 membrane delivery because Ca v 1.3 lacking ankyrin binding still displayed a greatly reduced but detectable current. 
Loss of I
Atrial Myocytes
Our results identify a direct association of ankyrin-B with Ca v 1.3 and a striking reduction of Ca v 1.3 and I Ca,L in primary ankyrin-B ϩ/Ϫ atrial cardiomyocytes. To test whether observed differences in I Ca,L in ankyrin-B ϩ/Ϫ atrial myocytes are sufficient to account for dramatic action potential shortening and AF susceptibility, we performed computational modeling of WT and ankyrin-B ϩ/Ϫ atrial action potentials ( Figure 5 ). We first incorporated experimentally measured changes in I Ca,L ( Figure 2 ) and I NCX ( Figure II in the online-only Data Supplement) and reduction in Na ϩ ,K ϩ -ATPase expression 12, 22 into a physiological and wellvalidated model of the atrial action potential from Nattel and colleagues. 23 Decreasing all 3 currents was sufficient to reduce the action potential nearly 25%, similar to the observed differences in APDs between ankyrin-B ϩ/Ϫ and WT atrial myocytes ( Figure 5B and 5G) . We next simulated action potentials in atrial myocytes deficient in Na ϩ -Ca 2ϩ exchange (NCX), Na ϩ ,K ϩ -ATPase, or I Ca,L and compared APDs with those in the WT model ( Figure 5K ). Reduction of Together, these findings provide additional data that associates reduced ankyrin-B function with human atrial disease.
Discussion
Ankyrin-B, required for the targeting and stability of critical membrane and submembrane molecules, 18, 24, 25 is important for normal membrane excitability in multiple cardiac cell types. 26 The multifunctional capacity of ankyrin-B is evident in the strong link between ankyrin dysfunction and a spectrum of cardiac disorders collectively referred to as ankyrin-B syndrome. In this study, we identify the L-type calcium channel 1.3 (␣1D) as a novel ankyrin-B-binding partner and provide an association between decreased ankyrin-B function and AF. Specifically, we demonstrate early-onset familial AF in human patients with an ANK2 missense mutation. Ankyrin-B ϩ/Ϫ mice display similar atrial dysfunction including increased incidence of spontaneous AF episodes and enhanced susceptibility to burst pacing-induced AF. At the cellular level, ankyrin-B ϩ/Ϫ atrial myocytes exhibit decreased I Ca,L and shortened APD, both hallmarks of clinical AF. 5, 27 There is a strong association between reduced I Ca,L and AF. 27 Although it is unclear whether I Ca,L dysfunction is a cause or effect of AF, there are numerous examples of AF linked to reduced I Ca,L . Atrial tissues from human AF patients display reduced mRNA expression of L-type Ca 2ϩ channels Ca v 1.2 and Ca v 1.3 in addition to an overall decrease in I Ca,L . 28, 29 In addition, patients with loss-of-function mutations in L-type Ca 2ϩ channel Ca v 1.2 manifest complex cardiac phenotypes including AF. 30 Similarly, atrial myocytes from Ca v 1.3 Ϫ/Ϫ mice exhibit reduced I Ca,L , a depolarizing shift in voltage-dependent I Ca,L activation (Ca v 1.3 activates at more negative potentials than Ca v 1.2), 31 and increased AF susceptibility on burst-pacing stimulation. 31, 32 Given the increased susceptibility to AF in Ca v 1.3 Ϫ/Ϫ mice and our findings that Ca v 1.3 membrane targeting is regulated by a direct interaction with ankyrin-B, it will be critical in future experiments to determine the direct role of Ca v 1.3 dysfunction in human ANK2-related atrial disease.
An intriguing finding from this study is that despite overlapping expression patterns of the L-type calcium channel ␣-subunits in atrial cells, ankyrin-B preferentially interacts with Ca v 1.3 and not Ca v 1.2 in atrial myocytes. A second interesting observation is that Ca v 1.3 is expressed, albeit to a lesser extent, in membranes of ankyrin-B Ϫ/Ϫ cells, suggesting that ankyrin-independent mechanisms also contribute to Ca v 1.3 membrane expression. These observations are consistent with L-type calcium channels interacting with a variety of signaling and scaffolding proteins that influence membrane expression. Some of the molecular mechanisms that regulate L-type calcium channel membrane expression include channel auxiliary subunits (␤-subunits), 33 signaling molecules (calmodulin), 34 and scaffolding/adapter proteins (␣-actinin2, A-kinase anchoring protein 79). 35 Expression levels are shown relative to calsequestrin (CSQ) expression to correct for potential minor differences in protein loading.
